Beskrivelse
Krav
IPC-klasse
Fullmektig i Norge:
Org.nummer: 979993269
- Org.nummer:
- Foretaksnavn:
- Foretaksform:
- Næring:
-
Forretningsadresse:
Fullmektig i EP:
2007.08.16, US 956273 P
BAILON P ET AL: "Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 12, no. 2, 1 March 2001 (2001-03-01), pages 195-202, XP002264676, ISSN: 1043-1802, DOI: 10.1021/BC000082G (B1)
WO-A2-2006/084089 (B1)
BASU AMARTYA ET AL: "STRUCTURE-FUNCTION ENGINEERING OF INTERFERON-BETA-1B FOR IMPROVING STABILITY, SOLUBILITY, POTENCY, IMMUNOGENICITY, AND PHARMACOKINETIC PROPERTIES BY SITE-SELECTIVE MONO-PEGYLATION", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 17, no. 3, 1 January 2006 (2006-01-01), pages 618-630, XP008078006, ISSN: 1043-1802, DOI: 10.1021/BC050322Y (B1)
EP-A2- 0 809 996 (B1)
EP-A2- 1 869 079 (B1)
HSU SHIH-JER ET AL: "Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C", JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, vol. 120, no. 3, 1 March 2021 (2021-03-01) , pages 956-964, XP055789197, HK ISSN: 0929-6646, DOI: 10.1016/j.jfma.2020.09.018 (B1)
HUANG YI-WEN ET AL: "Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B", HEPATOLOGY INTERNATIONAL, vol. 14, no. 6, 24 October 2018 (2018-10-24), pages 997-1008, XP037334123, ISSN: 1936-0533, DOI: 10.1007/S12072-020-10098-Y (B1)
ROBERTS M J ET AL: "Chemistry for peptide and protein PEGylation", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 54, no. 4, 17 June 2002 (2002-06-17), pages 459-476, XP002293146, ISSN: 0169-409X, DOI: 10.1016/S0169-409X(02)00022-4 (B1)
US-A- 5 932 462 (B1)
US-A- 5 951 974 (B1)
US-A1- 2005 009 988 (B1)
US-A1- 2006 057 070 (B1)
WO-A1-95/11924 (B1)
WO-A1-96/21469 (B1)
WO-A1-98/41562 (B1)
WO-A2-03/044056 (B1)
WO-A2-2005/000359 (B1)
BAKER DARREN P ET AL: "N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 17, no. 1, 18 January 2006 (2006-01-18), pages 179-188, XP002593171, ISSN: 1043-1802, DOI: 10.1021/BC050237Q [retrieved on 2005-12-03] (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Registreringsbrev (3210) (PTEP2205281)
|
Innkommende, AR501799166
Korrespondanse (Hovedbrev inn)
|
Utgående
EP formelle mangler
|
Innkommende, AR500612032
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
Årsavgift 17. avg. år (EP) | 2024.08.09 | 7150 | CPA GLOBAL LIMITED | Betalt og godkjent |
Årsavgift 16. avg. år (EP) | 2023.08.29 | 5200 | COMPUTER PACKAGES INC. | Betalt og godkjent |
32210577 expand_more expand_less | 2022.08.29 | 5500 | BRYN AARFLOT AS | Betalt |
Valideringsgebyr EP-patent
5500 = 1 X 5500
|
||||
Årsavgift 15. avg. år (EP) | 2022.08.29 | 4850 | COMPUTER PACKAGES INC. | Betalt og godkjent |